Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,025,813 papers from all fields of science
Search
Sign In
Create Free Account
BNP 1350
Known as:
BNP-1350
, BNP1350
, DB 172
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
cositecan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.
Deepika Rajesh
,
H. Robins
,
S. Howard
Journal of Neurology and Neuromedicine
2016
Corpus ID: 24125977
The poor prognosis of malignant glioma patients highlights the need to develop low toxicity, tumor specific agents with the…
Expand
Highly Cited
2009
Highly Cited
2009
Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors
R. Oostendorp
,
E. van de Steeg
,
+4 authors
J. Schellens
Drug Metabolism And Disposition
2009
Corpus ID: 26966662
Organic anion-transporting polypeptides (OATPs) are important uptake transporters that can have a profound impact on the systemic…
Expand
2005
2005
Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study
A. Daud
,
N. Valkov
,
+9 authors
D. Sullivan
Clinical Cancer Research
2005
Corpus ID: 2663389
Purpose: A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacy and…
Expand
2004
2004
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates
P. Thompson
,
S. Berg
,
+6 authors
S. Blaney
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 20965276
PurposeBNP1350 (7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, karenitecin), a highly lipophilic camptothecin, a high percentage…
Expand
2002
2002
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: Determination of efficacy and possible mechanisms of resistance
A. H. van Hattum
,
H. M. Schlüper
,
F. Hausheer
,
H. Pinedo
,
E. Boven
International Journal of Cancer
2002
Corpus ID: 11327378
The novel camptothecin derivative BNP1350 (7‐[2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin), also known as Karenitecin, has been…
Expand
2002
2002
Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
M. Yin
,
G. Hapke
,
+4 authors
Y. Rustum
Biochemical and Biophysical Research…
2002
Corpus ID: 25538538
Highly Cited
2001
Highly Cited
2001
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
M. Maliepaard
,
M. A. van Gastelen
,
+6 authors
J. Schellens
Clinical Cancer Research
2001
Corpus ID: 16242000
This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8…
Expand
2001
2001
The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer
M. Yin
,
G. Hapke
,
B. Guo
,
R. Azrak
,
C. Frank
,
Y. Rustum
Oncogene
2001
Corpus ID: 21373444
Promotion of apoptosis may potentiate the sensitivity of tumor cells to chemotherapeutic agents, thus improving the efficacy of…
Expand
Highly Cited
2000
Highly Cited
2000
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer
A. H. van Hattum
,
H. Pinedo
,
H. M. Schlüper
,
F. Hausheer
,
E. Boven
International Journal of Cancer
2000
Corpus ID: 5812467
BNP1350, 7‐[(2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin, is a novel semi‐synthetic, highly lipophilic, silicon‐containing…
Expand
2000
2000
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
M. Yin
,
B. Guo
,
+6 authors
Y. Rustum
Molecular Pharmacology
2000
Corpus ID: 9724662
Cellular topoisomerase I is an important target in cancer chemotherapy. A novel karenitecin, BNP1350, is a topoisomerase I…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE